Intrinsic Aggregation Propensity of the P63 and P73 TI Domains Correlates with P53R175H Interaction and Suggests Further Significance of Aggregation Events in the P53 Family

Overview

Journal Cell Death Differ

Specialty Cell Biology

Date 2016 Jul 23

PMID 27447112

Citations 32

Authors

Sebastian Kehrloesser

Christian Osterburg

Marcel Tuppi

Birgit Schafer

Karen Heather Vousden

Volker Dotsch

Affiliations

Soon will be listed here.

Abstract

The high percentage of p53 missense mutations found in cancer has been attributed to mutant acquired oncogenic gain of functions. Different aspects of these tumour-promoting functions are caused by repression of the transcriptional activity of p53 family members p63 and p73. A subset of frequently occurring p53 mutations results in thermodynamic destabilisation of the DNA-binding domain (DBD) rendering this domain highly unstable. These conformational mutants (such as p53R175H) have been suggested to directly bind to p63 and p73 via a co-aggregation mechanism mediated by their DBDs. Although the DBDs of p63 and p73 are in fact not sufficient for the interaction as shown previously, we demonstrate here that the transactivation inhibitory (TI) domains within the α-isoform-specific C termini of p63 and p73 are essential for binding to p53R175H. Hence, the closed dimeric conformation of inactive TAp63α that renders the TI domain inaccessible prevents efficient interaction. We further show that binding to p53R175H correlates with an intrinsic aggregation propensity of the tetrameric α-isoforms conferred by an openly accessible TI domain again supporting interaction via a co-aggregation mechanism.

Citing Articles

Oncogenic p53 triggers amyloid aggregation of p63 and p73 liquid droplets.

Petronilho E, de Andrade G, de Sousa G, Almeida F, Mota M, Gomes A Commun Chem. 2024; 7(1):207.

PMID: 39284933 PMC: 11405828. DOI: 10.1038/s42004-024-01289-x.

p63: a crucial player in epithelial stemness regulation.

Li Y, Giovannini S, Wang T, Fang J, Li P, Shao C Oncogene. 2023; 42(46):3371-3384.

PMID: 37848625 PMC: 10638092. DOI: 10.1038/s41388-023-02859-4.

Synuclein Proteins in Cancer Development and Progression.

Zanotti L, Malizia F, Cesatti Laluce N, Avila A, Mamberto M, Anselmino L Biomolecules. 2023; 13(6).

PMID: 37371560 PMC: 10296229. DOI: 10.3390/biom13060980.

The dual role of p63 in cancer.

Xu Y, Yang X, Xiong Q, Han J, Zhu Q Front Oncol. 2023; 13:1116061.

PMID: 37182132 PMC: 10174455. DOI: 10.3389/fonc.2023.1116061.

PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinoma.

Paz M, Ferretti G, Martins-Dinis M, Ferreira B, Faier-Pereira A, Barnoud T Front Mol Biosci. 2023; 10:1165132.

PMID: 37101558 PMC: 10123287. DOI: 10.3389/fmolb.2023.1165132.

References

Natan E, Joerger A . Structure and kinetic stability of the p63 tetramerization domain. J Mol Biol. 2011; 415(3):503-13. PMC: 3277882. DOI: 10.1016/j.jmb.2011.11.007. View

Ramsey M, He L, Forster N, Ory B, Ellisen L . Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. Cancer Res. 2011; 71(13):4373-9. PMC: 3129427. DOI: 10.1158/0008-5472.CAN-11-0046. View

Joerger A, Rajagopalan S, Natan E, Veprintsev D, Robinson C, Fersht A . Structural evolution of p53, p63, and p73: implication for heterotetramer formation. Proc Natl Acad Sci U S A. 2009; 106(42):17705-10. PMC: 2764906. DOI: 10.1073/pnas.0905867106. View

Talos F, Nemajerova A, Flores E, Petrenko O, Moll U . p73 suppresses polyploidy and aneuploidy in the absence of functional p53. Mol Cell. 2007; 27(4):647-59. DOI: 10.1016/j.molcel.2007.06.036. View

Chi S, Ayed A, Arrowsmith C . Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain. EMBO J. 1999; 18(16):4438-45. PMC: 1171518. DOI: 10.1093/emboj/18.16.4438. View

Trinidad A, Muller P, Cuellar J, Klejnot M, Nobis M, Valpuesta J . Interaction of p53 with the CCT complex promotes protein folding and wild-type p53 activity. Mol Cell. 2013; 50(6):805-17. PMC: 3699784. DOI: 10.1016/j.molcel.2013.05.002. View

Oren M, Rotter V . Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010; 2(2):a001107. PMC: 2828285. DOI: 10.1101/cshperspect.a001107. View

Brandt T, Petrovich M, Joerger A, Veprintsev D . Conservation of DNA-binding specificity and oligomerisation properties within the p53 family. BMC Genomics. 2009; 10:628. PMC: 2807882. DOI: 10.1186/1471-2164-10-628. View

Rinne T, Bolat E, Meijer R, Scheffer H, van Bokhoven H . Spectrum of p63 mutations in a selected patient cohort affected with ankyloblepharon-ectodermal defects-cleft lip/palate syndrome (AEC). Am J Med Genet A. 2009; 149A(9):1948-51. DOI: 10.1002/ajmg.a.32793. View

10.

Xu J, Reumers J, Couceiro J, De Smet F, Gallardo R, Rudyak S . Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol. 2011; 7(5):285-95. DOI: 10.1038/nchembio.546. View

11.

Lubin D, Butler J, Loh S . Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function. J Mol Biol. 2009; 395(4):705-16. DOI: 10.1016/j.jmb.2009.11.013. View

12.

Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C . A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol. 2001; 21(5):1874-87. PMC: 86759. DOI: 10.1128/MCB.21.5.1874-1887.2001. View

13.

Muller P, Caswell P, Doyle B, Iwanicki M, Tan E, Karim S . Mutant p53 drives invasion by promoting integrin recycling. Cell. 2010; 139(7):1327-41. DOI: 10.1016/j.cell.2009.11.026. View

14.

Tucci P, Agostini M, Grespi F, Markert E, Terrinoni A, Vousden K . Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A. 2012; 109(38):15312-7. PMC: 3458363. DOI: 10.1073/pnas.1110977109. View

15.

Wang G, Fersht A . Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding. Proc Natl Acad Sci U S A. 2015; 112(8):2443-8. PMC: 4345553. DOI: 10.1073/pnas.1500262112. View

16.

Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L . Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem. 2000; 275(38):29503-12. DOI: 10.1074/jbc.M003360200. View

17.

Flores E, Sengupta S, Miller J, Newman J, Bronson R, Crowley D . Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell. 2005; 7(4):363-73. DOI: 10.1016/j.ccr.2005.02.019. View

18.

Serber Z, Lai H, Yang A, Ou H, Sigal M, Kelly A . A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol. 2002; 22(24):8601-11. PMC: 139862. DOI: 10.1128/MCB.22.24.8601-8611.2002. View

19.

McGrath J, Duijf P, Doetsch V, Irvine A, De Waal R, Vanmolkot K . Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. Hum Mol Genet. 2001; 10(3):221-9. DOI: 10.1093/hmg/10.3.221. View

20.

Laurikkala J, Mikkola M, James M, Tummers M, Mills A, Thesleff I . p63 regulates multiple signalling pathways required for ectodermal organogenesis and differentiation. Development. 2006; 133(8):1553-63. DOI: 10.1242/dev.02325. View